Jones S M, Ellis J F, Russell P, Griffin K F, Oyston P C F
Microbiology, Dstl, CBS Porton Down, Salisbury, Wiltshire SP4 0JQ, UK and *National Laboratory for Zoonotic Diseases and Special Pathogens, Canadian Science Centre for Human and Animal Health, Winnipeg, Manitoba R3E 3R2, Canada.
J Med Microbiol. 2002 Dec;51(12):1055-1062. doi: 10.1099/0022-1317-51-12-1055.
Burkholderia pseudomallei, the aetiological agent of melioidosis, is endemic in south-east Asia and northern Australia, where it is an important cause of human disease. There is no vaccine available and antibiotic therapy is associated with high relapse rates. A panel of seven monoclonal antibodies (MAbs) that recognise capsular polysaccharide, lipopolysaccharide or proteins was produced and their ability to protect mice passively against experimental melioidosis was evaluated. The MAbs were capable of protecting mice against intra-peritoneal challenge with 10(4) cfu/250 MLD of a virulent strain of B. pseudomallei (NCTC 4845), when pooled, and four of the MAbs were individually protective. However, at a higher B. pseudomallei challenge level of 10(6) cfu none of the MAbs afforded protection and only the anti-exopolysaccharide MAbs produced a significantly delayed time to death.
类鼻疽杆菌是类鼻疽病的病原体，在东南亚和澳大利亚北部为地方病，是当地人类疾病的重要病因。目前尚无可用疫苗，抗生素治疗的复发率很高。制备了一组七种可识别荚膜多糖、脂多糖或蛋白质的单克隆抗体（MAb），并评估了它们被动保护小鼠抵抗实验性类鼻疽病的能力。这些单克隆抗体混合使用时能够保护小鼠抵抗腹腔注射10⁴cfu/250 MLD的强毒类鼻疽杆菌菌株（NCTC 4845），其中四种单克隆抗体单独使用时具有保护作用。然而，在更高的类鼻疽杆菌攻击水平10⁶cfu时，没有一种单克隆抗体能提供保护，只有抗胞外多糖单克隆抗体显著延迟了死亡时间。
